Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Oncolytic virus-based delivery of self-amplifying RNA therapeutics
EF 2022-23
Résumé
With developments in immunotherapy, a form of cancer therapy that stimulates a patient's immune system against their own cancer, there has been a tremendous increase in cancer patients' quality of life (QOL) and survival. However, this improvement does not extend to all cancer types. Many existing immunotherapies work well at combatting liquid tumours such as leukemias, but their success in solid tumours is limited. Tumours are more than just cancer cells; they are an ecosystem of cells that communicate with each other to grow and hide from the immune system. This ecosystem is called the tumour microenvironment (TME). Since the TME of solid tumours is tightly packed and immunosuppressive, it is difficult to target them with immunotherapy. Solid tumours make up 90% of cancer cases and are currently treated with surgery, radiation and chemotherapy which can cause serious side effects and discomfort for patients compared to immunotherapy. To be able to target solid tumours with immunotherapy, we must find a way to remodel the TME to make it more susceptible to this kind of treatment. To achieve this, we are designing a virus that can deliver TME-remodelling genes (TRGs) directly to the tumour. These TRGS can self-replicate and spread between cancer cells using the FAST protein which forms channels between cancer cells in close contact. Since cancer cells are clustered in solid tumours, the FAST protein can form channels between them, promoting the spread of TRGs across the entire tumour. If this therapy is successful, we will investigate the ways we can remodel the TME to make it more responsive to existing immunotherapies. This would allow patients to receive immunotherapies that were previously unavailable to them, improving the QOL and survival of all cancer patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486210
Name
Thomas Dylan A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Oncolytic virus-based delivery of self-amplifying RNA therapeutics
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Fast Protein; Immunotherapies; Oncolytic Virus; Self-Amplifying Rna; Solid Tumours; Vaccinia Virus
Abstract
With developments in immunotherapy, a form of cancer therapy that stimulates a patient's immune system against their own cancer, there has been a tremendous increase in cancer patients' quality of life (QOL) and survival. However, this improvement does not extend to all cancer types. Many existing immunotherapies work well at combatting liquid tumours such as leukemias, but their success in solid tumours is limited. Tumours are more than just cancer cells; they are an ecosystem of cells that communicate with each other to grow and hide from the immune system. This ecosystem is called the tumour microenvironment (TME). Since the TME of solid tumours is tightly packed and immunosuppressive, it is difficult to target them with immunotherapy. Solid tumours make up 90% of cancer cases and are currently treated with surgery, radiation and chemotherapy which can cause serious side effects and discomfort for patients compared to immunotherapy. To be able to target solid tumours with immunotherapy, we must find a way to remodel the TME to make it more susceptible to this kind of treatment. To achieve this, we are designing a virus that can deliver TME-remodelling genes (TRGs) directly to the tumour. These TRGS can self-replicate and spread between cancer cells using the FAST protein which forms channels between cancer cells in close contact. Since cancer cells are clustered in solid tumours, the FAST protein can form channels between them, promoting the spread of TRGs across the entire tumour. If this therapy is successful, we will investigate the ways we can remodel the TME to make it more responsive to existing immunotherapies. This would allow patients to receive immunotherapies that were previously unavailable to them, improving the QOL and survival of all cancer patients.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Thomas, Dylan A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~